UB Paderborn / Katalog / Suche / in CDI

In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017

Journal of medical microbiology, 2020-02, Vol.69 (2), p.207-217

2020

Volltextzugriff (PDF)

Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17

Journal of antimicrobial chemotherapy, 2019-08, Vol.74 (8), p.2284-2288

2019

Volltextzugriff (PDF)

Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016–2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam

Journal of global antimicrobial resistance., 2021-06, Vol.25, p.93-101

2021

Volltextzugriff (PDF)

In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020

Journal of global antimicrobial resistance., 2023-06, Vol.33, p.304-320

2023

Volltextzugriff (PDF)

Susceptibility of ceftobiprole against Gram-positive and Gram-negative clinical isolates from 2019 from different European territories

Journal of global antimicrobial resistance., 2022-06, Vol.29, p.393-397

2022

Volltextzugriff (PDF)

Surveillance of ceftobiprole against Gram-positive and Gram-negative clinical isolates from 2018 from different European territories

Journal of global antimicrobial resistance., 2021-09, Vol.26, p.326-329

2021

Volltextzugriff (PDF)

Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates

Journal of global antimicrobial resistance., 2024-09, Vol.38, p.71-82

2024

Volltextzugriff (PDF)

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii

Antibiotics (Basel), 2022-09, Vol.11 (9), p.1201

2022

Volltextzugriff (PDF)

P476 Monitoring antifungal resistance in a global collection of Candida spp. surveillance isolates, including C. auris —analysis of resistance in antifungals (ARIA) 2020 study

Medical mycology (Oxford), 2022-09, Vol.60 (Supplement_1)

2022

Volltextzugriff (PDF)

358. Surveillance of Activity of Antifungals: Data from the Analysis of Resistance in Antifungals (ARIA) 2020 Study

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

2131. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against Clinical Acinetobacter Isolates from China

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Volltextzugriff (PDF)

2132. Surveillance of Eravacycline Against Enterobacterales and Non-Fermenter Clinical Isolates, Including Resistant Isolates, Collected Worldwide from Multiple Infection Sites During 2021

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Volltextzugriff (PDF)

1945. Antibacterial activity of cefepime/enmetazobactam and comparator agents against U.S. Enterobacterales clinical isolates collected from 2019-2021

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Volltextzugriff (PDF)

2133. Surveillance of Eravacycline Against Gram-positive Clinical Pathogens, Including Resistant Isolates, Collected Worldwide From Multiple Infection Sites During 2021

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Volltextzugriff (PDF)

1678. Activity of mecillinam against urinary tract clinical isolates from the United States during 2017-2020 including isolates resistant to comparator antibiotics and multi-drug resistant isolates

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

1679. Susceptibility of Gram-Negative Clinical Isolates Collected from the USA in 2020 to Eravacycline and Comparators

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

In vitro susceptibility testing of ceftobiprole against 880 European respiratory tract infection isolates of methicillin-resistant Staphylococcus aureus followed by whole genome sequencing of ceftobiprole-resistant isolates

Diagnostic microbiology and infectious disease, 2020-04, Vol.96 (4), p.114978-114978, Article 114978

2020

Volltextzugriff (PDF)

Pediatric Rotavirus Gastroenteritis: A 2 year Analysis to Understand Current Prevalence in Mumbai

Online journal of health & allied sciences : OJHAS, 2011-04, Vol.10 (1)

2011

Volltextzugriff (PDF)

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy—SMART 2017–2021

European journal of clinical microbiology & infectious diseases, 2024-07, Vol.43 (7), p.1343-1348

2024

Volltextzugriff (PDF)

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant IAcinetobacter baumannii/I

Antibiotics (Basel), 2022-09, Vol.11 (9)

2022

Volltextzugriff (PDF)

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)—SMART 2017–21

JAC-antimicrobial resistance, 2023-08, Vol.5 (4), p.dlad098-dlad098

2023

Volltextzugriff (PDF)

1359. Activity of Meropenem/Nacubactam Combination Against Gram-Negative Clinical Isolates: ROSCO Global Surveillance 2017

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S416-S416

2018

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017

Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17

Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016–2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam

In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020

Susceptibility of ceftobiprole against Gram-positive and Gram-negative clinical isolates from 2019 from different European territories

Surveillance of ceftobiprole against Gram-positive and Gram-negative clinical isolates from 2018 from different European territories

Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii

P476 Monitoring antifungal resistance in a global collection of Candida spp. surveillance isolates, including C. auris —analysis of resistance in antifungals (ARIA) 2020 study

358. Surveillance of Activity of Antifungals: Data from the Analysis of Resistance in Antifungals (ARIA) 2020 Study

2131. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against Clinical Acinetobacter Isolates from China

2132. Surveillance of Eravacycline Against Enterobacterales and Non-Fermenter Clinical Isolates, Including Resistant Isolates, Collected Worldwide from Multiple Infection Sites During 2021

1945. Antibacterial activity of cefepime/enmetazobactam and comparator agents against U.S. Enterobacterales clinical isolates collected from 2019-2021

2133. Surveillance of Eravacycline Against Gram-positive Clinical Pathogens, Including Resistant Isolates, Collected Worldwide From Multiple Infection Sites During 2021

1678. Activity of mecillinam against urinary tract clinical isolates from the United States during 2017-2020 including isolates resistant to comparator antibiotics and multi-drug resistant isolates

1679. Susceptibility of Gram-Negative Clinical Isolates Collected from the USA in 2020 to Eravacycline and Comparators

In vitro susceptibility testing of ceftobiprole against 880 European respiratory tract infection isolates of methicillin-resistant Staphylococcus aureus followed by whole genome sequencing of ceftobiprole-resistant isolates

Pediatric Rotavirus Gastroenteritis: A 2 year Analysis to Understand Current Prevalence in Mumbai

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy—SMART 2017–2021

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant IAcinetobacter baumannii/I

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)—SMART 2017–21

1359. Activity of Meropenem/Nacubactam Combination Against Gram-Negative Clinical Isolates: ROSCO Global Surveillance 2017

Suchergebnisse filtern